Zymeworks Statistics
Total Valuation
Zymeworks has a market cap or net worth of $1.87 billion. The enterprise value is $1.59 billion.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zymeworks has 74.84 million shares outstanding. The number of shares has increased by 0.46% in one year.
| Current Share Class | 74.84M |
| Shares Outstanding | 74.84M |
| Shares Change (YoY) | +0.46% |
| Shares Change (QoQ) | -2.07% |
| Owned by Insiders (%) | 0.84% |
| Owned by Institutions (%) | 59.24% |
| Float | 74.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.98 |
| Forward PS | 21.05 |
| PB Ratio | 5.87 |
| P/TBV Ratio | 6.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.94, with a Debt / Equity ratio of 0.06.
| Current Ratio | 6.94 |
| Quick Ratio | 6.69 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -18.46% and return on invested capital (ROIC) is -12.15%.
| Return on Equity (ROE) | -18.46% |
| Return on Assets (ROA) | -9.98% |
| Return on Invested Capital (ROIC) | -12.15% |
| Return on Capital Employed (ROCE) | -19.88% |
| Revenue Per Employee | $470,213 |
| Profits Per Employee | -$221,773 |
| Employee Count | 286 |
| Asset Turnover | 0.30 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zymeworks has paid $7.36 million in taxes.
| Income Tax | 7.36M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +74.88% in the last 52 weeks. The beta is 1.31, so Zymeworks's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | +74.88% |
| 50-Day Moving Average | 18.37 |
| 200-Day Moving Average | 14.25 |
| Relative Strength Index (RSI) | 72.64 |
| Average Volume (20 Days) | 1,902,006 |
Short Selling Information
The latest short interest is 7.53 million, so 10.06% of the outstanding shares have been sold short.
| Short Interest | 7.53M |
| Short Previous Month | 7.05M |
| Short % of Shares Out | 10.06% |
| Short % of Float | 10.15% |
| Short Ratio (days to cover) | 8.75 |
Income Statement
In the last 12 months, Zymeworks had revenue of $134.48 million and -$63.43 million in losses. Loss per share was -$0.84.
| Revenue | 134.48M |
| Gross Profit | -8.35M |
| Operating Income | -70.61M |
| Pretax Income | -56.07M |
| Net Income | -63.43M |
| EBITDA | -60.97M |
| EBIT | -70.61M |
| Loss Per Share | -$0.84 |
Full Income StatementBalance Sheet
The company has $251.93 million in cash and $18.90 million in debt, giving a net cash position of $280.46 million or $3.75 per share.
| Cash & Cash Equivalents | 251.93M |
| Total Debt | 18.90M |
| Net Cash | 280.46M |
| Net Cash Per Share | $3.75 |
| Equity (Book Value) | 320.06M |
| Book Value Per Share | 4.26 |
| Working Capital | 249.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$64.24 million and capital expenditures -$1.25 million, giving a free cash flow of -$65.50 million.
| Operating Cash Flow | -64.24M |
| Capital Expenditures | -1.25M |
| Free Cash Flow | -65.50M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
Gross margin is -6.21%, with operating and profit margins of -52.51% and -47.16%.
| Gross Margin | -6.21% |
| Operating Margin | -52.51% |
| Pretax Margin | -41.69% |
| Profit Margin | -47.16% |
| EBITDA Margin | -45.34% |
| EBIT Margin | -52.51% |
| FCF Margin | n/a |
Dividends & Yields
Zymeworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.46% |
| Shareholder Yield | -0.46% |
| Earnings Yield | -3.39% |
| FCF Yield | -3.50% |
Analyst Forecast
The average price target for Zymeworks is $28.00, which is 12.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $28.00 |
| Price Target Difference | 12.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 38.29% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zymeworks has an Altman Z-Score of 4.81 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.81 |
| Piotroski F-Score | 3 |
